Clinical Trial

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 8, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-19.
Trial Details
NCT Number NCT06607731
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Conditions Bone Angioma
Enrollment 11 participants
Start Date 2024-06-25
Primary Completion 2024-12 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-08